Related Experiment Video

Updated: Jan 7, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

An AKR1C3-activated kinase inhibitor prodrug

Zhengnian Li1, Michael Martinez1, Woong Sub Byun1

  • 1Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine, Stanford University Stanford CA USA nsgray01@stanford.edu hinshaw@stanford.edu.

RSC Chemical Biology
|January 5, 2026
PubMed

Insights

Researchers developed novel AKR1C3-activated prodrugs of a CDK11 inhibitor. This strategy converts selective kinase inhibitors into context-dependent prodrugs, potentially sparing normal tissue and improving therapeutic windows.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Enzymatically activated prodrugs offer targeted inhibition by leveraging specific enzyme activity within tumors.
  • AKR1C3 (aldo-keto reductase 1C3) is overexpressed in tumors and catalyzes prodrug activation.
  • Previous AKR1C3-activated prodrugs released non-selective toxins; this study explores activating selective inhibitors.

Purpose of the Study:

  • To develop AKR1C3-activated prodrugs of OTS964, a selective CDK11 inhibitor.
  • To demonstrate that this prodrug strategy can create context-dependent inhibitors.
  • To assess the potential for improved therapeutic windows in cancer treatment.

Main Methods:

  • Synthesis of novel AKR1C3-activated prodrugs of OTS964.
  • Biochemical assays to confirm AKR1C3-specific activation.
  • Cellular assays to evaluate the prodrugs' efficacy and recapitulation of parent compound activity.

Main Results:

  • The lead prodrug demonstrated specific activation by AKR1C3.
  • Enzymatic conversion of the prodrug resulted in cellular activity mirroring the parent compound (OTS964).
  • The AKR1C3-activated prodrug strategy successfully converted a selective kinase inhibitor into a context-dependent agent.

Conclusions:

  • The AKR1C3-activated prodrug strategy is effective for creating context-dependent inhibitors from selective kinase inhibitors.
  • This approach holds promise for developing targeted cancer therapies with reduced toxicity to normal tissues.
  • Further development may lead to improved therapeutic options with enhanced safety profiles.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

Related Concept Videos

Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
435
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K